-- First Fully-Integrated and Validated Assessments of Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) Provide Oncologists with a Single Testing Solution to Guide Personalized Immunotherapy-based Treatment Plans --
"Cancer immunotherapies are at the forefront of cancer treatment, and
new, quantitative approaches are needed to predict clinical responses to
this important, but also expensive, class of therapies," said
A growing body of evidence, most recently presented
"The ability to accurately measure multiple biomarkers simultaneously,
including TMB and MSI, is an important advance for the field of cancer
immunotherapy, and one that is unique to Foundation Medicine," said
"We were encouraged by the findings presented at ASCO, including the
possibility of identifying patients more likely to benefit from
checkpoint inhibitor immunotherapy," said
Independent of the FoundationOne and FoundationOne Heme assays,
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of FoundationOne and FoundationOne Heme to identify and predict the likelihood of response to immunotherapies, and the ability of FoundationOne and FoundationOne Heme to inform therapeutic choices in cancer, including leading to physician-directed therapy changes and to improve patient outcomes. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
These risks and uncertainties include the risks that the company's TMB and MSI analysis do not perform as expected or the results thereof are not widely accepted; subsequent research renders TMB and/or MSI status less useful or not useful in clinical practice; physicians may not be able to obtain access to relevant targeted therapies, immunotherapies or clinical trials matched to molecular findings identified by FoundationOne or FoundationOne Heme as readily as expected; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended December 31, 2015, which is on file with the Securities and Exchange Commission, as well as other risks detailed in subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.
News Provided by Acquire Media